康辰药业：目前公司经营稳健，不存在应披露而未披露事项

Core Viewpoint - Kangchen Pharmaceutical (603590) is currently operating steadily and is adhering to regulatory requirements for information disclosure, with no undisclosed matters [1] Group 1: Company Operations - The progress of projects KC1086, KC1036, and ZY5301 is in line with expectations, with the clinical trial application for KC1086 having received FDA approval [1] - The marketing transformation has shifted from an alliance model to a self-operated dual-driven approach, significantly enhancing operational efficiency [1] Group 2: Financial Actions - The company is implementing a share buyback plan ranging from 50 million to 100 million yuan for employee stock ownership or equity incentives [1] Group 3: Business Growth - The overseas business of the company continues to grow steadily [1]